GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder

Taro Kishi, Hiroshi Ichinose, Reiji Yoshimura, Yasuhisa Fukuo, Tsuyoshi Kitajima, Toshiya Inada, Hiroshi Kunugi, Tadafumi Kato, Takeo Yoshikawa, Hiroshi Ujike, Giovanna M. Musso, Wakako Umene-Nakano, Jun Nakamura, Norio Ozaki, Nakao Iwata

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Tetrahydrobiopterin (BH4) plays an important role in the biosynthesis of serotonin, melatonin and catecholamines, all of which are implicated in the pathophysiology of mood disorders (MDs), including major depressive disorder (MDD) and bipolar disorder (BP). Production of BH4 is regulated by GTP cyclohydrolase transcription and activity. Thus, we considered the GTP cyclohydrolase gene (GCH1) to be a good candidate gene in the pathophysiology of MDs and of the serotonin selective reuptake inhibitors (SSRIs) response in MDD, and conducted a case-control study utilizing three SNPs (rs8007267, rs3783641 and rs841) and moderate sample sizes (405 MDD patients, including 262 patients treated by SSRIs, 1022 BP patients and 1805 controls). Method: A multiple logistic regression analysis was carried out to compare the frequencies of each SNP genotype for the target phenotype across patients and controls in several genetic models, while adjusting for possible confounding factors. A clinical response was defined as a decrease of more than 50% from the baseline score on the Structured Interview Guide for Hamilton Rating Scale for Depression (SIGH-D) within 8 weeks, and clinical remission as a SIGH-D score of less than 7 at 8 weeks. Result: No associations between three SNPs in GCH1 and MDD or BP were observed; however, GCH1 was associated with SSRI therapeutic response in MDD in all the marker's haplotype analysis (Global P value=0.0379). Conclusions: Results suggest that GCH1 may predict response to SSRI in MDD in the Japanese population. Nevertheless, a replication study using larger samples may be required for conclusive results, since our sample size was small.

Original languageEnglish
Pages (from-to)315-322
Number of pages8
JournalJournal of Affective Disorders
Volume142
Issue number1-3
DOIs
Publication statusPublished - 15-12-2012

Fingerprint

GTP Cyclohydrolase
Major Depressive Disorder
Serotonin Uptake Inhibitors
Haplotypes
Bipolar Disorder
Genes
Single Nucleotide Polymorphism
Mood Disorders
Sample Size
Genetic Models
Melatonin
Catecholamines
Case-Control Studies
Serotonin
Logistic Models
Genotype
Regression Analysis
Interviews
Depression
Phenotype

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Kishi, Taro ; Ichinose, Hiroshi ; Yoshimura, Reiji ; Fukuo, Yasuhisa ; Kitajima, Tsuyoshi ; Inada, Toshiya ; Kunugi, Hiroshi ; Kato, Tadafumi ; Yoshikawa, Takeo ; Ujike, Hiroshi ; Musso, Giovanna M. ; Umene-Nakano, Wakako ; Nakamura, Jun ; Ozaki, Norio ; Iwata, Nakao. / GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder. In: Journal of Affective Disorders. 2012 ; Vol. 142, No. 1-3. pp. 315-322.
@article{b96b8cb4522f49cdaa1c65f50ff706ea,
title = "GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder",
abstract = "Background: Tetrahydrobiopterin (BH4) plays an important role in the biosynthesis of serotonin, melatonin and catecholamines, all of which are implicated in the pathophysiology of mood disorders (MDs), including major depressive disorder (MDD) and bipolar disorder (BP). Production of BH4 is regulated by GTP cyclohydrolase transcription and activity. Thus, we considered the GTP cyclohydrolase gene (GCH1) to be a good candidate gene in the pathophysiology of MDs and of the serotonin selective reuptake inhibitors (SSRIs) response in MDD, and conducted a case-control study utilizing three SNPs (rs8007267, rs3783641 and rs841) and moderate sample sizes (405 MDD patients, including 262 patients treated by SSRIs, 1022 BP patients and 1805 controls). Method: A multiple logistic regression analysis was carried out to compare the frequencies of each SNP genotype for the target phenotype across patients and controls in several genetic models, while adjusting for possible confounding factors. A clinical response was defined as a decrease of more than 50{\%} from the baseline score on the Structured Interview Guide for Hamilton Rating Scale for Depression (SIGH-D) within 8 weeks, and clinical remission as a SIGH-D score of less than 7 at 8 weeks. Result: No associations between three SNPs in GCH1 and MDD or BP were observed; however, GCH1 was associated with SSRI therapeutic response in MDD in all the marker's haplotype analysis (Global P value=0.0379). Conclusions: Results suggest that GCH1 may predict response to SSRI in MDD in the Japanese population. Nevertheless, a replication study using larger samples may be required for conclusive results, since our sample size was small.",
author = "Taro Kishi and Hiroshi Ichinose and Reiji Yoshimura and Yasuhisa Fukuo and Tsuyoshi Kitajima and Toshiya Inada and Hiroshi Kunugi and Tadafumi Kato and Takeo Yoshikawa and Hiroshi Ujike and Musso, {Giovanna M.} and Wakako Umene-Nakano and Jun Nakamura and Norio Ozaki and Nakao Iwata",
year = "2012",
month = "12",
day = "15",
doi = "10.1016/j.jad.2012.05.004",
language = "English",
volume = "142",
pages = "315--322",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "1-3",

}

Kishi, T, Ichinose, H, Yoshimura, R, Fukuo, Y, Kitajima, T, Inada, T, Kunugi, H, Kato, T, Yoshikawa, T, Ujike, H, Musso, GM, Umene-Nakano, W, Nakamura, J, Ozaki, N & Iwata, N 2012, 'GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder', Journal of Affective Disorders, vol. 142, no. 1-3, pp. 315-322. https://doi.org/10.1016/j.jad.2012.05.004

GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder. / Kishi, Taro; Ichinose, Hiroshi; Yoshimura, Reiji; Fukuo, Yasuhisa; Kitajima, Tsuyoshi; Inada, Toshiya; Kunugi, Hiroshi; Kato, Tadafumi; Yoshikawa, Takeo; Ujike, Hiroshi; Musso, Giovanna M.; Umene-Nakano, Wakako; Nakamura, Jun; Ozaki, Norio; Iwata, Nakao.

In: Journal of Affective Disorders, Vol. 142, No. 1-3, 15.12.2012, p. 315-322.

Research output: Contribution to journalArticle

TY - JOUR

T1 - GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder

AU - Kishi, Taro

AU - Ichinose, Hiroshi

AU - Yoshimura, Reiji

AU - Fukuo, Yasuhisa

AU - Kitajima, Tsuyoshi

AU - Inada, Toshiya

AU - Kunugi, Hiroshi

AU - Kato, Tadafumi

AU - Yoshikawa, Takeo

AU - Ujike, Hiroshi

AU - Musso, Giovanna M.

AU - Umene-Nakano, Wakako

AU - Nakamura, Jun

AU - Ozaki, Norio

AU - Iwata, Nakao

PY - 2012/12/15

Y1 - 2012/12/15

N2 - Background: Tetrahydrobiopterin (BH4) plays an important role in the biosynthesis of serotonin, melatonin and catecholamines, all of which are implicated in the pathophysiology of mood disorders (MDs), including major depressive disorder (MDD) and bipolar disorder (BP). Production of BH4 is regulated by GTP cyclohydrolase transcription and activity. Thus, we considered the GTP cyclohydrolase gene (GCH1) to be a good candidate gene in the pathophysiology of MDs and of the serotonin selective reuptake inhibitors (SSRIs) response in MDD, and conducted a case-control study utilizing three SNPs (rs8007267, rs3783641 and rs841) and moderate sample sizes (405 MDD patients, including 262 patients treated by SSRIs, 1022 BP patients and 1805 controls). Method: A multiple logistic regression analysis was carried out to compare the frequencies of each SNP genotype for the target phenotype across patients and controls in several genetic models, while adjusting for possible confounding factors. A clinical response was defined as a decrease of more than 50% from the baseline score on the Structured Interview Guide for Hamilton Rating Scale for Depression (SIGH-D) within 8 weeks, and clinical remission as a SIGH-D score of less than 7 at 8 weeks. Result: No associations between three SNPs in GCH1 and MDD or BP were observed; however, GCH1 was associated with SSRI therapeutic response in MDD in all the marker's haplotype analysis (Global P value=0.0379). Conclusions: Results suggest that GCH1 may predict response to SSRI in MDD in the Japanese population. Nevertheless, a replication study using larger samples may be required for conclusive results, since our sample size was small.

AB - Background: Tetrahydrobiopterin (BH4) plays an important role in the biosynthesis of serotonin, melatonin and catecholamines, all of which are implicated in the pathophysiology of mood disorders (MDs), including major depressive disorder (MDD) and bipolar disorder (BP). Production of BH4 is regulated by GTP cyclohydrolase transcription and activity. Thus, we considered the GTP cyclohydrolase gene (GCH1) to be a good candidate gene in the pathophysiology of MDs and of the serotonin selective reuptake inhibitors (SSRIs) response in MDD, and conducted a case-control study utilizing three SNPs (rs8007267, rs3783641 and rs841) and moderate sample sizes (405 MDD patients, including 262 patients treated by SSRIs, 1022 BP patients and 1805 controls). Method: A multiple logistic regression analysis was carried out to compare the frequencies of each SNP genotype for the target phenotype across patients and controls in several genetic models, while adjusting for possible confounding factors. A clinical response was defined as a decrease of more than 50% from the baseline score on the Structured Interview Guide for Hamilton Rating Scale for Depression (SIGH-D) within 8 weeks, and clinical remission as a SIGH-D score of less than 7 at 8 weeks. Result: No associations between three SNPs in GCH1 and MDD or BP were observed; however, GCH1 was associated with SSRI therapeutic response in MDD in all the marker's haplotype analysis (Global P value=0.0379). Conclusions: Results suggest that GCH1 may predict response to SSRI in MDD in the Japanese population. Nevertheless, a replication study using larger samples may be required for conclusive results, since our sample size was small.

UR - http://www.scopus.com/inward/record.url?scp=84868118364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868118364&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2012.05.004

DO - 10.1016/j.jad.2012.05.004

M3 - Article

C2 - 22770721

AN - SCOPUS:84868118364

VL - 142

SP - 315

EP - 322

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 1-3

ER -